Q32 Bio Inc (QTTB)

Diyong Xu also bought $15mill of the offering 1,875,000 shares on 5/28 - a director

Orbimed Advisors added $15mill on 5/28 to bring their holdings to 17.4% or 4,127,987 shares

Q32 Bio Secures $55 Million Private Placement to Advance Alopecia Areata Pipeline (QTTB)May 27, 2026 11:53 AM
IH Market News Q32 Bio raised approximately $55 million in a private placement led by major healthcare investors as the company continues development of its Phase 2 alopecia areata therapy program. Key Investor Takeaways Q32 Bio (NASDAQ:QTTB) announced a $55 million private placement involving institutional and accredited investors. The financing was led by BVF Partners with participation from RA Capital Management, OrbiMed, and Atlas Venture. Proceeds may strengthen the company’s cash position as it advances bempikibart (ADX-914) in Phase 2 studies for alopecia areata. The offering includes common stock priced at $8.00 per share alongside pre-funded warrants. Investors may focus on how the financing impacts Q32 Bio’s development runway and future clinical milestones. Why QTTB Stock Is in Focus Q32 Bio Inc. (NASDAQ:QTTB) announced it entered into a securities purchase agreement for a private placement expected to generate approximately $55 million in gross proceeds. Under the terms of the financing, the company agreed to issue: 6,725,000 shares of common stock priced at $8.00 per share pre-funded warrants to purchase 150,000 shares at $7.9999 per warrant The warrants are immediately exercisable and remain outstanding until fully exercised. The transaction is expected to close on May 28, 2026, subject to customary closing conditions. The financing was led by BVF Partners L.P., with additional participation from: RA Capital Management OrbiMed Atlas Venture Morgan Stanley served as lead placement agent, while Oppenheimer & Co. acted as placement agent. Q32 Bio said the capital raise supports its ongoing development strategy centered on autoimmune and inflammatory disease therapies, particularly its lead alopecia areata candidate bempikibart (ADX-914). The company is currently advancing bempikibart, a fully human anti-IL-7Ra antibody, through an ongoing Phase 2 clinical program. According to Q32 Bio, the therapy is designed to help re-regulate adaptive immune function in alopecia areata and other T cell-mediated autoimmune diseases. Why This Matters for Investors The financing provides Q32 Bio with additional capital as clinical-stage biotechnology companies continue facing elevated funding pressures and long development timelines. For investors, participation from several well-known healthcare-focused institutional firms may be viewed as a signal of continued interest in the company’s autoimmune platform and alopecia areata program. The raise could also help reduce near-term financing risk while supporting ongoing clinical development activities. At the same time, the offering introduces dilution through the issuance of additional shares and warrants, which investors often closely evaluate in biotech financings. The company did not provide updated cash runway guidance or specify detailed allocation plans for the proceeds beyond advancing development efforts. Investor focus may therefore remain centered on: upcoming Phase 2 data regulatory progress future partnering opportunities broader autoimmune pipeline development Alopecia areata remains a competitive therapeutic market with growing industry interest, particularly in immune-regulating treatments targeting T cell pathways. What to Watch Next Investors may monitor: Progress from the ongoing Phase 2 bempikibart study Future clinical data releases Updated cash runway disclosures Regulatory interactions tied to alopecia areata development Additional autoimmune disease indications Potential business development or licensing activity Dilution impact from the financing structure Q32 Bio stock price Original: Q32 Bio Secures $55 Million Private Placement to Advance Alopecia Areata Pipeline (QTTB)

Very odd that stock goes up 67% on $55mil offering at $8

Maybe something huge is about to be made public? Who knows

Q32 Bio Announces $10.5 Million Registered Direct OfferingFebruary 17, 2026 6:59 AM
PR Newswire (US)

WALTHAM, Mass., Feb. 17, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced a $10.5 million registered direct offering. This transaction was led by a new institutional investor with participation by an existing dedicated public institutional investor.Q32 Bio has entered into a definitive agreement for the issuance and sale of 1,666,679 shares of common stock and pre-funded warrants to purchase up to 1,025,654 shares of common stock at an offering price of $3.90 per share of common stock, which was the closing price per share of Q32 Bio's common stock on Nasdaq on February 13, 2026, and $3.8999 per pre-funded warrant, which represents the price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the pre-funded warrants are exercised in full. The closing of the offering is expected to occur on or about February 18, 2026, subject to the satisfaction of customary closing conditions.The gross proceeds to Q32 Bio from this offering are expected to be approximately $10.5 million, before deducting certain offering expenses. Q32 Bio intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, for working capital purposes including expenses related to research, clinical development and commercialization efforts including for supporting the advancement of bempikibart into future clinical trials for the treatment of alopecia areata.The securities above are being offered pursuant to a shelf registration statement on Form S-3 (333-286491) that was filed with the Securities and Exchange Commission (the "SEC") on April 11, 2025, and was declared effective by the SEC on April 21, 2025. The offering is being made only by means of the written prospectus and prospectus supplement that form a part of the registration statement. A prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov.This press release does not constitute an offer to sell or the solicitation of offers to buy any of the securities being offered, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.1National Alopecia Areata FoundationForward-Looking StatementsThis communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements contained herein which do not describe historical facts are forward-looking statements, including, among others, the expected date of closing of the offering, the anticipated gross proceeds of the offering, the intended use of proceeds from the offering and the anticipated filing of the prospectus supplement in relation to the offering; which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.Forward-looking statements are based on management's current beliefs and assumptions, which are subject to risks and uncertainties and are not guarantees of future performance. Such risks and uncertainties include, among others, the risk that additional data, or the results of ongoing data analyses, may not support Q32 Bio's current beliefs and expectations for bempikibart, including with respect to the durability of clinical responses, safety profile, the risk that ongoing and future clinical studies, including that the SIGNAL-AA Part A OLE and topline results of the SIGNAL-AA Part B trial may not be completed by mid-2026 or at all, might be more costly than expected or might not yield anticipated results, that Q32 Bio may use its capital resources sooner than currently anticipated and such other risks and uncertainties identified in Q32 Bio's periodic, current and other filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and any subsequent filings with the SEC, which are available at the SEC's website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect Q32 Bio's results of operations and its cash flows, which would, in turn, have a significant and adverse impact on Q32 Bio's stock price. Q32 Bio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Q32 Bio disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.Contacts:
Investors: Brendan Burns
Argot Partners
212.600.1902
Q32Bio@argotpartners.comMedia: David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com





View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-announces-10-5-million-registered-direct-offering-302689038.htmlSOURCE Q32 Bio

Original: Q32 Bio Announces $10.5 Million Registered Direct Offering

Q32 Bio Sells Complement Inhibitor ADX-097
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata --

-- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 --

-- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales --

-- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these programs --

WALTHAM, Mass., Dec. 1, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (NASDAQ: AKBA) ("Akebia").

"This transaction strengthens our cash position through additional non-dilutive funding, extending our runway into the second half of 2027, as we remain focused on advancing bempikibart for patients with AA, an indication with significant unmet medical need. We believe bempikibart has tremendous potential to transform the AA treatment paradigm and we look forward to sharing topline data from Part B of the SIGNAL-AA Phase 2a trial, which remains on-track for mid-2026," said Jodie Morrison, Chief Executive Officer of Q32 Bio. "We are pleased to transition ownership and continued development of ADX-097 to Akebia, a company focused on developing and commercializing therapies for kidney disease."

ADX-097, the lead product candidate from Q32 Bio's tissue-targeted complement inhibitor platform, is a humanized anti-C3d Factor H monoclonal antibody ("mAb") fusion protein. ADX-097 is designed to inhibit complement activation—an integral part of the innate immune system—through a novel, tissue-targeted mechanism with potential in a range of indications associated with C3d deposition including kidney, autoimmune, vascular and skin diseases.

Q32 Bio's tissue-targeted complement platform is designed to inhibit complement activation in the tissue while minimizing systemic complement blockade, a key differentiator versus current complement therapeutics. The platform is proprietary to Q32 Bio and developed with foundational science from the University of Colorado Anschutz Medical Campus. Beyond ADX-097, discovery and earlier development efforts include ADX-096, a C3d mAb – CR1 fusion protein with preclinical data supportive of its use in ophthalmologic indications as well as potential utility in a broad range of other indications, and C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. Q32 Bio retains the rights to its wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets and is continuing to evaluate strategic options for these programs.

Akebia has acquired ADX-097 and will be responsible for future development and commercialization. Under the terms of the agreement, Q32 Bio will receive $12 million in upfront payments and a near-term milestone, which includes $7 million received at signing, $3 million at the 6-month anniversary of signing, and $2 million payable upon the earlier of the achievement of a milestone or the end of 2026. These payments as well as potential development, regulatory and commercial milestones total up to $592 million. Q32 Bio is also eligible to receive tiered royalties on potential future sales of ADX-097, ranging from low single-digit to mid-teen percentages.

Q32 Bio now expects its cash and cash equivalents, together with the upfront payments and near-term milestone from the sale of ADX-097, to fund operations into the second half of 2027, through the SIGNAL-AA Part A OLE and topline results of the SIGNAL-AA Part B trial expected in mid-2026.

About Q32 Bio

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a

IS THIS STOCK A SCAM OR WHAT??? I WANT THE TRUTH!!!

QTTB under $3

Badly oversold. Release the 13g and explode this. Any positive news will double this quickly.

I hope nobody is shorting QTTB this one about to fly really high.

nice rise, keeps going?

QTTB amazing many Ihubbers miss these profitable trades